FAVORITO TAMARA A 4

What Happened

• Tamara A. Favorito, a director of Zevra Therapeutics (ZVRA), was granted a derivative award of 30,000 shares on June 4, 2026. The award is a stock option-type grant with an exercise price equal to the closing price of ZVRA common stock on Nasdaq on the grant date, so there was no immediate intrinsic value and no cash changed hands. The grant was made as compensation for board service.

Key Details

• Transaction date: June 4, 2026; Form 4 filed June 18, 2026 (appears to be filed 14 days after the grant).
• Grant size and terms: 30,000 shares (derivative award); exercise price = closing price on June 4, 2026 (per footnote).
• Vesting: 100% vests on the earlier of (i) one year after grant, (ii) the day before the first annual meeting after grant, or (iii) immediately prior to a change in control — subject to continued service.
• Award source: Issued under the company’s non‑employee director compensation policy.
• Shares owned after transaction: not disclosed in the summary provided.
• Filing timeliness: filing date suggests a delayed Form 4; late filings can affect transparency but do not change the grant terms.

Context

• This was an equity compensation grant (derivative award) rather than a buy or sell; because the exercise price equals market price at grant, the award had no immediate in‑the‑money value. Such grants are common for non‑employee directors and are typically intended to align long‑term interests with shareholders.